Market Place
Sourcing Support
NewAmsterdam Completes Enrollment For Obicetrapib-Ezetimibe Combo TANDEM Trial
08 Jul 2024 //
GLOBENEWSWIRE
FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets
26 Apr 2024 //
FDA
Enforcement Report - Week of April 24, 2024
24 Apr 2024 //
FDA
Egis` medicines won the Innovation Grand Prize
26 Mar 2024 //
PRESS RELEASE
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
22 Mar 2024 //
BUSINESSWIRE
FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
22 Mar 2024 //
BUSINESSWIRE
NewAmsterdam #Doses First Patient in Phase 3 Evaluating Obicetrapib & Ezetimibe
12 Mar 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of September 13, 2023
13 Sep 2023 //
FDA
Miller Law& Motley Ric Announce a Proposed Settlement Zetia Antitrust Litigation
27 Jun 2023 //
PR NEWSWIRE
NewAmsterdam Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib
03 Jun 2023 //
GLOBENEWSWIRE
Merck, Glenmark put their Zetia antitrust case to bed
25 Apr 2023 //
FIERCE PHARMA
Merck, Glenmark must face jury trial in Zetia antitrust case
15 Feb 2023 //
FIERCE PHARMA
NewAmsterdam notches another win in resurrection of Amgen cardio drug
18 Jan 2023 //
ENDPTS
Orient`s Generic Ezetimibe Receives Approval in the U.S.
13 Sep 2022 //
FDA
NewAmsterdam Pharma Announces Publication in Nature Medicine
11 Aug 2022 //
BUSINESSWIRE
Hetero Lab III Generic Ezetimibe Receives Approval in the U.S.
26 Jul 2022 //
FDA
FDA Issues Untitled Letter to Althera for Statements Relating to ROSZET
24 Jun 2022 //
LEXBLOG
FDA slams Althera for misleading ad with dearth of safety info & dubious stats
08 Jun 2022 //
ENDPTS
Esperion Supports Collaborative Study with NC to Study the Effects of NEXLIZET
25 Apr 2022 //
PRESS RELEASE
NewAmsterdam Pharma Begins Dosing in Phase 2 Trial of Obicetrapib + zetimibe
05 Apr 2022 //
BUSINESSWIRE
Enforcement Report - Week of November 17, 2021
17 Nov 2021 //
FDA
Now Available: Generic Ezetimibe-Rosuvastatin Combination Tablets - In A Trial
15 Nov 2021 //
EINNEWS
Enforcement Report - Week of November 11, 2021
10 Nov 2021 //
FDA
Esperion to cute 170 staffers as heart disease pill sputters
19 Oct 2021 //
YAHOOFINANCE
FDA Approves Althera’s Roszet (rosuvastatin and ezetimibe)
31 Mar 2021 //
PRWEB
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
19 Mar 2021 //
PHARMATIMES
Esperion Therapeutics (ESPR) Announces EC Approval of NUSTENDI Tablet
06 Apr 2020 //
STREETINSIDER
Esperion`s Nexletol busts cholesterol levels regardless , ezitimibe therapy
30 Mar 2020 //
ESPERION
Esperion Announces Pooled Analyses from Ph3 LDL-C Lowering NEXLETOL™
23 Mar 2020 //
GLOBENEWSWIRE
Esperion gets FDA thumbs up for cholesterol drug Nexletol
26 Feb 2020 //
PMLIVE
Givlaari, Nubeqa among Jan CHMP decisions
03 Feb 2020 //
PHARMATIMES
CHMP issues +ve opinions for bempedoic acid and the bempedoic acid / ezetimib
31 Jan 2020 //
BUSINESSWIRE
MedCo builds its case for star cholesterol RNAi therapy
25 Sep 2019 //
ENDPTS
Esperion’s Bempedoic Acid/ Ezetimibe Tablet Achieves Positive Phase II Results
02 Sep 2019 //
CONTRACT PHARMA
Sanofi receive favourable US court ruling in Praluent patent litigation
30 Aug 2019 //
PHARMABIZ
Armed stellar if niche PhIII, Regeneron steers `breakthrough` cholesterol drug
14 Aug 2019 //
ENDPTS
Esperion and Oberland Capital Announce $200 Million Funding Agreement
27 Jun 2019 //
BIOSPACE
EMA validates Daiichi Sankyo & Esperion`s MAA for bempedoic acid
01 Mar 2019 //
PHARMABIZ
Daiichi Sankyo Europe & Esperion Announce Validation of MAA for Bempedoic Acid
28 Feb 2019 //
PR NEWSWIRE
Esperion licenses European rights on cholesterol drug for $300M
05 Jan 2019 //
BIOPHARMA DIVE
Clinical development of fixed combination medicinal products
17 Dec 2018 //
Ezetimibe product-specific bioequivalence guidance
17 Dec 2018 //
EMA
New drug options, risk factors added to U.S. heart guidelines
12 Nov 2018 //
ECONOMIC TIMES
New drug options, risk factors added to U.S. heart guidelines
12 Nov 2018 //
ECONOMIC TIMES
Accord Healthcare`s Generic Ezetimibe Receives Approval in US
01 Nov 2018 //
FDA
Merck CEO to stay on through 2019
26 Sep 2018 //
BIOPHARMA DIVE
Lawyers Compete To Represent Zetia Buyers In Antitrust Case
30 Jul 2018 //
LAW360
FTC imposes conditions on Amneal acquisition of Impax
11 Jul 2018 //
PHARMA LETTER
Esperion`s LDL drug aces a third pivotal trial
24 May 2018 //
FIERCE BIOTECH
To shame drugmakers, CMS publicizes price hikes
17 May 2018 //
BIOPHARMADIVE
ANI Pharmaceuticals Completes Acq.of Generic Products & Assets from Amneal/Impax
07 May 2018 //
PR NEWSWIRE
Sanofi, Regeneron to cut price of Praluent
13 Mar 2018 //
FORBES
Esperion`s Cholesterol Drug Positive in PhIII Trial
08 Mar 2018 //
BIOSPACE
Alkem Labs Generic Ezetimibe; Simvastatin Receives Approval In US
28 Dec 2017 //
FDA
Alkem Labs Generic Ezetimibe Receives Approval In US
27 Dec 2017 //
FDA
Amneal Pharm’s Generic Ezetimibe; Simvastatin Receives Approval In US
22 Nov 2017 //
FDA
Merck plots 1,800 sales layoffs and new chronic care focus
21 Oct 2017 //
FIERCE PHARMA
CETP inhibitor class finally dies as Merck abandons anacetrapib
13 Oct 2017 //
PMLIVE
Aurobindo Pharma’s Generic Ezetimibe Receives Approval In US
30 Aug 2017 //
FDA
